ASCO 2023 | Investigating durable treatment strategies following progression in kidney cancer

David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how median overall-survival (OS) has significantly improved over the last thirty years for patients with advanced kidney cancer. First-line therapy with immuno-oncology/tyrosine kinase inhibitors (IO/TKIs) showed encouraging response rates and progression-free survival (PFS). In terms of OS, rates have become more modest, suggesting issues with durability for patients with kidney cancer. Conversely, in purely immunotherapeutic regimens, responses tend to be durable. The CONTACT-03 trial (NCT04338269) aimed to assess treatment strategies following progression on anti-PD1 based therapy through either TKIs or in combination with anti-PD1 rechallenge. For many patients, IO rechallenge was deemed unnecessary and caused higher rates of toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.